Maslimomab
NY (what is this?) (verify) Intracellular
(initiation)
Intracellular
(reception)
Extracellular
Unsorted
Maslimomab is a mouse monoclonal antibody[1] and an immunosuppressive drug.[2] It is an anti-human T-cell receptor alpha/beta chain.[1]
References
- ^ a b "Proposed International Nonproprietary Names: Maslimomab" (PDF). WHO Drug Information. 5 (4). Geneva: World Health Organization: 201. 1991. Archived from the original (PDF) on 23 February 2012.
- ^ Pelletier JP, Mukhtar F (January 2020). "Passive monoclonal and polyclonal antibody therapies.". Immunologic Concepts in Transfusion Medicine. Philadelphia: Elsevier. pp. 251–348 (299). doi:10.1016/B978-0-323-67509-3.00016-0. ISBN 978-0-323-67510-9. PMC 7153350.
- v
- t
- e
Immunosuppressive drugs / Immunosuppressants (L04)
(initiation)
Antimetabolites |
|
---|---|
Macrolides/ other IL-2 inhibitors |
|
IMiDs |
(reception)
IL-1 receptor antagonists | |
---|---|
mTOR |
Antibodies |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
-cept (Fusion) |
- Avacopan
- Baricitinib
- Bimekizumab
- Blisibimod
- Briakinumab
- Brodalumab
- Canakinumab
- Crovalimab
- Danicopan]
- Deucravacitinib
- Efgartigimod alfa (+hyaluronidase)
- Etrasimod
- Filgotinib
- Fingolimod
- Guselkumab
- Iptacopan
- Itacitinib
- Ixekizumab
- Netakimab
- Olokizumab
- Ozanimod
- Peficitinib
- Pegcetacoplan
- Ponesimod
- Ravulizumab
- Risankizumab
- Ritlecitinib
- Rozanolixizumab
- Sarilumab
- Satralizumab
- Siltuximab
- Siponimod
- Sirukumab
- Spesolimab
- Sutimlimab
- Tildrakizumab
- Tofacitinib
- Upadacitinib
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e